抗体薬物複合体の世界市場レポート 2025年

抗体薬物複合体市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR23.2％で383億9,000万米ドルに成長します。予測期間の成長は、次世代ADCS、適応症の拡大、個別化医療への注目の高まり、精密医療への投資の増加、ヘルスケア意識の高まりに起因すると考えられます。予測期間における主な動向としては、コンジュゲーション技術の進歩、腫瘍生物学に対する理解の向上、技術の進歩、治療用途の拡大、コンジュゲーション技術の高度化などが挙げられます。

抗体薬物複合体の世界市場は、世界のがん罹患率の上昇に牽引されて大きな成長を遂げています。肥満、喫煙、飲酒、食生活の乱れなど、ほとんどのがんの主な原因が増加傾向に寄与しています。英国がん研究協会（Cancer Research UK）は、2040年までに年間2,750万人が新たにがんに罹患すると推定し、大幅な増加を予測しています。このようながん罹患数の急増は、抗体薬物複合体の需要を押し上げ、市場の成長を促進すると予想されます。

抗体薬物複合体市場の成長軌道は、臨床試験数の増加によってさらに加速しています。臨床試験は、新しい治療や介入を試験するために不可欠であり、疾病管理において重要な役割を果たしています。抗体薬物複合体は抗がん剤の重要なカテゴリーとして、血液関連のがんや固形がんの治療のために多くの臨床試験が行われています。特に、2023年5月にXtalksが報告したように、ClinicalTrials.govに登録された臨床試験は452,604件で、世界中で大幅に増加しています。この増加傾向は、臨床試験の重要性が高まっていることを示しており、抗体薬物複合体市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗体薬物複合体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗体薬物複合体市場：成長率分析
• 世界の抗体薬物複合体市場の実績：規模と成長, 2019-2024
• 世界の抗体薬物複合体市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗体薬物複合体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗体薬物複合体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• リンカ
• 薬物/毒素
• その他のタイプ
• 世界の抗体薬物複合体市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アドサーティス
• カドシラ
• その他の製品
• 世界の抗体薬物複合体市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫原技術
• シアトルジェネティクステクノロジー
• 免疫医療技術
• その他のテクノロジー
• 世界の抗体薬物複合体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液がん
• 乳がん
• 卵巣がん
• 肺がん
• 脳腫瘍
• その他の用途
• 世界の抗体薬物複合体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の抗体薬物複合体市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgGベースのモノクローナル抗体
• IgMベースのモノクローナル抗体
• 二重特異性抗体
• 世界の抗体薬物複合体市場、リンカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 切断可能なリンカー
• 切断不可能なリンカー
• 安定したリンカー
• 世界の抗体薬物複合体市場薬物/毒素の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞毒性薬
• 化学療法剤
• 放射性同位元素
• 世界の抗体薬物複合体市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素標的ADC
• 免疫調節剤を含む抗体薬物複合体

第7章 地域別・国別分析

• 世界の抗体薬物複合体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗体薬物複合体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗体薬物複合体市場：競合情勢
• 抗体薬物複合体市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Millennium Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Daiichi Sankyo Company Limited
• Sorrento Therapeutics Inc.
• Astellas Pharma Inc.
• Zydus Lifesciences Limited
• Seagen Inc.
• Seagen Inc.
• Synthon BV
• Genentech Inc.
• ImmunoGen Inc.
• Nordic Nanovector ASA
• ADC Therapeutics SA
• Immunomedics Inc.
• Mersana Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗体薬物複合体市場2029：新たな機会を提供する国
• 抗体薬物複合体市場2029：新たな機会を提供するセグメント
• 抗体薬物複合体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antibody-drug conjugates (ADCs) are medications specifically designed to deliver chemotherapy to cancer cells. They consist of a cytotoxic drug linked to a monoclonal antibody, which binds to a specific target expressed on cancer cells. Upon binding to the target, the ADC releases a cytotoxic chemical into the cancer cell, aiming to destroy it.

The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.

The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $13.57 billion in 2024 to $16.66 billion in 2025 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to increasing prevalence of cancer, clinical success and approvals, strategic collaborations, growing investment in R&D, market expansion strategies.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $38.39 billion in 2029 at a compound annual growth rate (CAGR) of 23.2%. The growth in the forecast period can be attributed to next generation ADCS, expanding indications, increasing focus on personalized medicine, rising investment in precision medicine, increasing healthcare awareness. Major trends in the forecast period include advancements in conjugation technologies, improved understanding of tumor biology, technological advancements, expanding therapeutic application, advanced conjugation technologies.

The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.

The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.

Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.

Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.

Leading companies in the antibody-drug conjugates (ADCs) market are introducing groundbreaking conjugates, including the first single-use reactor specifically designed for ADC manufacturing. This innovative single-use reactor facilitates faster, more flexible, and contamination-free production of targeted cancer therapies by eliminating the need for cleaning and sterilization between batches. For example, in September 2024, Merck & Co., Inc., a US-based pharmaceutical company, launched the Mobius ADC reactor. This cutting-edge reactor addresses the growing demand for more efficient and safer manufacturing processes for ADCs, achieving a 70% increase in efficiency while significantly reducing the risks of cross-contamination and the labor-intensive cleaning associated with traditional stainless steel or glass reactors. The Mobius ADC Reactor utilizes Ultimus Film technology, which enhances bag strength, durability, and leak resistance, ensuring superior product quality.

Major companies operating in the antibody drug conjugates market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Linker; Drug/Toxin; Other Types
• 2) By Product: Adcertis; Kadcyla; Other Products
• 3) By Technology: Immunogen Technology; Seattle Genetics Technology; Immunomedics Technology; Other Technology
• 4) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
• 5) By End User: Hospital; Clinics; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies; IgM-based Monoclonal Antibodies; Bispecific Antibodies
• 2) By Linker: Cleavable Linkers; Non-cleavable Linkers; Stable Linkers
• 3) By Drug/Toxin: Cytotoxic Drugs; Chemotherapeutic Agents; Radioisotopes
• 4) By Other Types: Enzyme-Targeted ADCs; Antibody-Drug Conjugates with Immune Modulators
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibody Drug Conjugates Market Characteristics

3. Antibody Drug Conjugates Market Trends And Strategies

4. Antibody Drug Conjugates Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antibody Drug Conjugates Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antibody Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antibody Drug Conjugates Market Growth Rate Analysis
• 5.4. Global Antibody Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antibody Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antibody Drug Conjugates Total Addressable Market (TAM)

6. Antibody Drug Conjugates Market Segmentation

• 6.1. Global Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Linker
• Drug/Toxin
• Other Types
• 6.2. Global Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adcertis
• Kadcyla
• Other Products
• 6.3. Global Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunogen Technology
• Seattle Genetics Technology
• Immunomedics Technology
• Other Technology
• 6.4. Global Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor
• Other Applications
• 6.5. Global Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Other End Users
• 6.6. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG-based Monoclonal Antibodies
• IgM-based Monoclonal Antibodies
• Bispecific Antibodies
• 6.7. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Linker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linkers
• Non-cleavable Linkers
• Stable Linkers
• 6.8. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Drug/Toxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytotoxic Drugs
• Chemotherapeutic Agents
• Radioisotopes
• 6.9. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme-Targeted ADCs
• Antibody-Drug Conjugates with Immune Modulators

7. Antibody Drug Conjugates Market Regional And Country Analysis

• 7.1. Global Antibody Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antibody Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antibody Drug Conjugates Market

• 8.1. Asia-Pacific Antibody Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antibody Drug Conjugates Market

• 9.1. China Antibody Drug Conjugates Market Overview
• 9.2. China Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antibody Drug Conjugates Market

• 10.1. India Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antibody Drug Conjugates Market

• 11.1. Japan Antibody Drug Conjugates Market Overview
• 11.2. Japan Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antibody Drug Conjugates Market

• 12.1. Australia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antibody Drug Conjugates Market

• 13.1. Indonesia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antibody Drug Conjugates Market

• 14.1. South Korea Antibody Drug Conjugates Market Overview
• 14.2. South Korea Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antibody Drug Conjugates Market

• 15.1. Western Europe Antibody Drug Conjugates Market Overview
• 15.2. Western Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antibody Drug Conjugates Market

• 16.1. UK Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antibody Drug Conjugates Market

• 17.1. Germany Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antibody Drug Conjugates Market

• 18.1. France Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antibody Drug Conjugates Market

• 19.1. Italy Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antibody Drug Conjugates Market

• 20.1. Spain Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antibody Drug Conjugates Market

• 21.1. Eastern Europe Antibody Drug Conjugates Market Overview
• 21.2. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antibody Drug Conjugates Market

• 22.1. Russia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antibody Drug Conjugates Market

• 23.1. North America Antibody Drug Conjugates Market Overview
• 23.2. North America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antibody Drug Conjugates Market

• 24.1. USA Antibody Drug Conjugates Market Overview
• 24.2. USA Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antibody Drug Conjugates Market

• 25.1. Canada Antibody Drug Conjugates Market Overview
• 25.2. Canada Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antibody Drug Conjugates Market

• 26.1. South America Antibody Drug Conjugates Market Overview
• 26.2. South America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antibody Drug Conjugates Market

• 27.1. Brazil Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antibody Drug Conjugates Market

• 28.1. Middle East Antibody Drug Conjugates Market Overview
• 28.2. Middle East Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antibody Drug Conjugates Market

• 29.1. Africa Antibody Drug Conjugates Market Overview
• 29.2. Africa Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antibody Drug Conjugates Market Competitive Landscape And Company Profiles

• 30.1. Antibody Drug Conjugates Market Competitive Landscape
• 30.2. Antibody Drug Conjugates Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Antibody Drug Conjugates Market Other Major And Innovative Companies

• 31.1. Millennium Pharmaceuticals Inc.
• 31.2. Gilead Sciences Inc.
• 31.3. Daiichi Sankyo Company Limited
• 31.4. Sorrento Therapeutics Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Zydus Lifesciences Limited
• 31.7. Seagen Inc.
• 31.8. Seagen Inc.
• 31.9. Synthon BV
• 31.10. Genentech Inc.
• 31.11. ImmunoGen Inc.
• 31.12. Nordic Nanovector ASA
• 31.13. ADC Therapeutics SA
• 31.14. Immunomedics Inc.
• 31.15. Mersana Therapeutics Inc.

32. Global Antibody Drug Conjugates Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antibody Drug Conjugates Market

34. Recent Developments In The Antibody Drug Conjugates Market

35. Antibody Drug Conjugates Market High Potential Countries, Segments and Strategies

• 35.1 Antibody Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antibody Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antibody Drug Conjugates Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer